DrugPatentWatch Database Preview
Try a free trialSee Plans and Pricing
« Back to Dashboard
The generic ingredient in DOVATO is dolutegravir sodium; lamivudine. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dolutegravir sodium; lamivudine profile page.
Generic Entry Opportunity Date for 211994
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 211994
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 50MG BASE;300MG|
|Approval Date:||Apr 8, 2019||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Apr 8, 2022|
|Regulatory Exclusivity Use:||NEW COMBINATION|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Oct 5, 2027||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Dec 8, 2029||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription